Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma

(MedPage Today) -- Daratumumab (Darzalex) plus the standard triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) significantly improved clinical outcomes versus VRd alone in patients with transplant-ineligible or...